These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25546798)

  • 21. Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G.
    Jindal G; Parmar VR; Gupta VK
    Pediatr Neurol; 2009 Dec; 41(6):451-2. PubMed ID: 19931169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B;
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulins: current understanding and future directions.
    Jolles S; Jordan SC; Orange JS; van Schaik IN
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):163-8. PubMed ID: 25546806
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous immunoglobulin and immune response.
    Kaveri SV; Lecerf M; Saha C; Kazatchkine MD; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):94-6. PubMed ID: 25546777
    [No Abstract]   [Full Text] [Related]  

  • 25. Complement-mediated cytotoxicity of antibodies to the GABA(B) receptor.
    Batocchi AP; Della Marca G; Frisullo G
    Lancet Neurol; 2010 Apr; 9(4):343; author reply 343-4. PubMed ID: 20298957
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment in inflammatory neuropathies.
    Hutton EJ; Lunn MP
    Expert Rev Clin Immunol; 2010 Mar; 6(2):231-45. PubMed ID: 20402386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considering the demand for and prioritization of intravenous immunoglobulin.
    Orange JS
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):78-82. PubMed ID: 25546771
    [No Abstract]   [Full Text] [Related]  

  • 28. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravenous immunoglobulin therapy in neurological diseases during pregnancy.
    Ringel I; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V70-4. PubMed ID: 16998758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.
    Kaveri SV; Mouthon L; Kazatchkine MD
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):6-8. PubMed ID: 7964857
    [No Abstract]   [Full Text] [Related]  

  • 32. [Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy].
    Gold R; Bayas A; Toyka KV
    Nervenarzt; 2005 Aug; 76(8):1009-21; quiz 1022-3. PubMed ID: 16080020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin as an intervention strategy of risk factor modification for prevention of severe infection in heart transplantation.
    Sarmiento E; Arraya M; Jaramillo M; Diez P; Fernandez-Yañez J; Palomo J; Navarro J; Carbone J
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):156-8. PubMed ID: 25546803
    [No Abstract]   [Full Text] [Related]  

  • 34. High-dose intravenous immunoglobulin therapy in dysimmune neuropathies.
    Nobile-Orazio E; Bersano A
    Neurol Sci; 2002 Apr; 23 Suppl 1():S25-32. PubMed ID: 12032584
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure.
    Bentley P; Rosso M; Sadnicka A; Israeli-Korn S; Laffan M; Sharma P
    J Clin Pharm Ther; 2012 Jun; 37(3):286-90. PubMed ID: 21767284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 7th International Immunoglobulin Conference: Immunomodulation.
    Danieli MG; Shoenfeld Y
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):123. PubMed ID: 25546788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovative uses of intravenous immunoglobulins in clinical hematology. Symposium. December 5, 1986, San Francisco, California. Proceedings.
    Am J Med; 1987 Oct; 83(4A):1-56. PubMed ID: 3118702
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
    Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin treatment in autoimmune neurological disorders--effects on quality of life.
    Padua L; Sabatelli M; Evoli A; Pazzaglia C; Tonali P
    Hum Immunol; 2005 Apr; 66(4):417-21. PubMed ID: 15866706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies.
    Cocito D; Serra G; Paolasso I; Barilà DA; Lopiano L; Cattel L
    J Peripher Nerv Syst; 2012 Dec; 17(4):426-8. PubMed ID: 23279347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.